Literature DB >> 23990339

Inflammation-induced catabolism of tryptophan and tyrosine in acute ischemic stroke.

Heidi Ormstad1, Robert Verkerk, Hans Christian D Aass, Karl-Friedrich Amthor, Leiv Sandvik.   

Abstract

Whether the inflammatory response that accompanies acute ischemic stroke induces the kynurenine pathway is currently a matter of conjecture. Activation of this pathway may disturb active metabolites. The aim of this study was thus to characterize the catabolism of tryptophan and tyrosine in acute ischemic stroke (AIS) patients, and its association with cytokines, C-reactive protein, and glucose. Serum levels of 5-hydroxytryptamine, tryptophan catabolites, and competing amino acids and significant ratios of these were measured in 45 AIS patients and compared to those of 40 control subjects. Furthermore, associations between the serum levels of these biomarkers and serum levels of cytokines, C-reactive protein, and glucose were determined. Significantly lower levels of tryptophan and tyrosine in the stroke group indicate increased tryptophan and tyrosine oxidation in acute ischemic stroke, while significantly lowered tryptophan index and tyrosine index indicate a reduced capacity for the synthesis of 5-hydroxytryptamine and catecholamines in the brain, respectively. Furthermore, our findings indicate that the proinflammatory response in acute ischemic stroke may be responsible for a reduced capacity for the biosynthesis of brain catecholamines and mediate neurotoxic effects. Meanwhile, the anti-inflammatory IL-10 may exert a neuroprotective effect and prevent the putative reduced capacity for 5-hydroxytryptamine synthesis in the brain. These mechanisms may be involved in several sequelae following stroke, such as cognitive impairment, depression, and fatigue.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23990339     DOI: 10.1007/s12031-013-0097-2

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  52 in total

Review 1.  Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.

Authors:  G C Prendergast; M Y Chang; L Mandik-Nayak; R Metz; A J Muller
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Prevalence of admission hyperglycaemia across clinical subtypes of acute stroke.

Authors:  J F Scott; G M Robinson; J M French; J E O'Connell; K G Alberti; C S Gray
Journal:  Lancet       Date:  1999-01-30       Impact factor: 79.321

3.  Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway.

Authors:  Michael Maes; Winfried Rief
Journal:  Psychiatry Res       Date:  2012-02-24       Impact factor: 3.222

Review 4.  Role of precursor availability in control of monoamine biosynthesis in brain.

Authors:  J D Fernstrom
Journal:  Physiol Rev       Date:  1983-04       Impact factor: 37.312

5.  Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.

Authors:  S Bonaccorso; A Puzella; V Marino; M Pasquini; M Biondi; M Artini; C Almerighi; M Levrero; B Egyed; E Bosmans; H Y Meltzer; M Maes
Journal:  Psychiatry Res       Date:  2001-12-15       Impact factor: 3.222

6.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

7.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

8.  Preconditioning to mild oxidative stress mediates astroglial neuroprotection in an IL-10-dependent manner.

Authors:  Niva Segev-Amzaleg; Dorit Trudler; Dan Frenkel
Journal:  Brain Behav Immun       Date:  2013-01-08       Impact factor: 7.217

9.  Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators.

Authors:  D Alberati-Giani; A M Cesura
Journal:  Amino Acids       Date:  1998       Impact factor: 3.520

10.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

View more
  13 in total

Review 1.  Executive (dys)function after stroke: special considerations for behavioral pharmacology.

Authors:  Jessica M Povroznik; Jenny E Ozga; Cole Vonder Haar; Elizabeth B Engler-Chiurazzi
Journal:  Behav Pharmacol       Date:  2018-10       Impact factor: 2.293

2.  New monocyte locomotion inhibitory factor analogs protect against cerebral ischemia-reperfusion injury in rats.

Authors:  Xiaoping Wang; Chao Wang; Yan Yang; Jingman Ni
Journal:  Bosn J Basic Med Sci       Date:  2017-08-20       Impact factor: 3.363

3.  Increases in Plasma Tryptophan Are Inversely Associated with Incident Cardiovascular Disease in the Prevención con Dieta Mediterránea (PREDIMED) Study.

Authors:  Edward Yu; Miguel Ruiz-Canela; Marta Guasch-Ferré; Yan Zheng; Estefania Toledo; Clary B Clish; Jordi Salas-Salvadó; Liming Liang; Dong D Wang; Dolores Corella; Montse Fitó; Enrique Gómez-Gracia; José Lapetra; Ramón Estruch; Emilio Ros; Montserrat Cofán; Fernando Arós; Dora Romaguera; Lluis Serra-Majem; Jose V Sorlí; Frank B Hu; Miguel A Martinez-Gonzalez
Journal:  J Nutr       Date:  2017-02-08       Impact factor: 4.798

4.  NMR plasma metabolomics study of patients overcoming acute myocardial infarction: in the first 12 h after onset of chest pain with statistical discrimination towards metabolomic biomarkers.

Authors:  M Petras; D Kalenska; M Samos; T Bolek; M Sarlinova; P Racay; E Halasova; O Strbak; J Stasko; L Musak; M Skorvanova; E Baranovicova
Journal:  Physiol Res       Date:  2020-09-09       Impact factor: 1.881

Review 5.  Kynurenines, Gender and Neuroinflammation; Showcase Schizophrenia.

Authors:  J de Bie; C K Lim; G J Guillemin
Journal:  Neurotox Res       Date:  2016-06-24       Impact factor: 3.911

6.  Response of Mammalian Macrophages to Challenge with the Chlorovirus Acanthocystis turfacea Chlorella Virus 1.

Authors:  Thomas M Petro; Irina V Agarkova; You Zhou; Robert H Yolken; James L Van Etten; David D Dunigan
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

7.  Activation of the kynurenine pathway in the acute phase of stroke and its role in fatigue and depression following stroke.

Authors:  Heidi Ormstad; Robert Verkerk; Karl-Friedrich Amthor; Leiv Sandvik
Journal:  J Mol Neurosci       Date:  2014-03-25       Impact factor: 3.444

8.  Sleep and Stroke: New Updates on Epidemiology, Pathophysiology, Assessment, and Treatment.

Authors:  H Lee Lau; Tanja Rundek; Alberto R Ramos
Journal:  Curr Sleep Med Rep       Date:  2019-05-02

9.  The combination of Astragalus membranaceus extract and ligustrazine to improve the inflammation in rats with thrombolytic cerebral ischemia.

Authors:  Ruihuan Pan; Mingchao Zhou; Yiping Zhong; Jingping Xie; Shanshan Ling; Xialin Tang; Yan Huang; Hongxia Chen
Journal:  Int J Immunopathol Pharmacol       Date:  2019 Jan-Dec       Impact factor: 3.219

10.  Tryptophan Metabolism, Inflammation, and Oxidative Stress in Patients with Neurovascular Disease.

Authors:  Martin Hajsl; Alzbeta Hlavackova; Karolina Broulikova; Martin Sramek; Martin Maly; Jan E Dyr; Jiri Suttnar
Journal:  Metabolites       Date:  2020-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.